An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–9. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wu X, Li G, Gao X, Zhai M, Chen W, Hu H, Tang Z. Prediction of radiosensitive patients with gastric cancer by developing gene signature. Int J Oncol. 2017;51(4):1067–1076. doi:10.3892/ijo.2017.4107.
   PubMed Web of Science ®Google Scholar
• Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol. 2010;40(Suppl 1):i28–37. doi:10.1093/jjco/hyq124.
   PubMed Web of Science ®Google Scholar
• Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi J-H, Kim H-K, Yu W. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396. doi:10.1016/S1470-2045(14)70473-5.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol. 2014;20:11567–11573. doi:10.3748/wjg.v20.i33.11567.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, et al. Survival outcomes of two phase 2 studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin for patients with gastric cancer after D2 gastrectomy. Ann Surg Oncol. 2019;26(2):465–472. doi:10.1245/s10434-018-7063-8.
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643–655. doi:10.1038/nrclinonc.2013.170.
   PubMed Web of Science ®Google Scholar
• Zali H, Rezaei-Tavirani M, Vafaee R, Rezaei-Tavirani M. Gastric cardia adenocarcinoma pathway analysis. Gastroenterol Hepatol Bed Bench. 2013;6:S11–18.
   PubMedGoogle Scholar
• Okines AF, Gonzalez de Castro D, Cunningham D, Chau I, Langley RE, Thompson LC, Stenning SP, Saffery C, Barbachano Y, Coxon F, et al. Biomarker analysis in oesophagogastric cancer: results from the REAL3 and TransMAGIC trials. Eur J Cancer. 2013;49:2116–2125. doi:10.1016/j.ejca.2013.02.007.
   PubMed Web of Science ®Google Scholar
• Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut. 2009;58:127–143. doi:10.1136/gut.2008.155861.
   PubMed Web of Science ®Google Scholar
• Miao Y, Sui J, Xu SY, Liang GY, Pu YP, Yin LH. Comprehensive analysis of a novel four-lncRNA signature as a prognostic biomarker for human gastric cancer. Oncotarget. 2017;8:75007–75024. doi:10.18632/oncotarget.20496.
   PubMedGoogle Scholar
• Lee J, Cristescu R, Kim KM, Kim K, Kim ST, Park SH, Kang WK. Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget. 2017;8:66305–66315. doi:10.18632/oncotarget.19985.
   PubMedGoogle Scholar
• Clermont PL, Fornaro L, Crea F. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer. Epigenomics. 2017;9:1329–1335. doi:10.2217/epi-2017-0074.
   PubMed Web of Science ®Google Scholar
• Song P, Jiang B, Liu Z, Ding J, Liu S, Guan W. A three-lncRNA expression signature associated with the prognosis of gastric cancer patients. Cancer Med. 2017;6:1154–1164. doi:10.1002/cam4.1047.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Hu Y, Li T, Yu J, Zhao L, Ye G, Deng H, Mou T, Cai S, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2018;267:504–513. doi:10.1097/SLA.0000000000002116.
   PubMed Web of Science ®Google Scholar
• Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, et al. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016;27(2):225–232. doi:10.1093/annonc/mdv560.
   PubMed Web of Science ®Google Scholar
• Lee HE, Chae SW, Lee YJ, Kim MA, Lee HS, Lee BL, Kim WH. Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer. Br J Cancer. 2008;99:1704–1711. doi:10.1038/sj.bjc.6604738.
   PubMed Web of Science ®Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. doi:10.1016/S0140-6736(18)30789-X.
   PubMed Web of Science ®Google Scholar
• Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, Park YK, Kim -H-H, Lee HS, Lee KH, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol. 2018;19:629–638. doi:10.1016/S1470-2045(18)30108-6.
   PubMed Web of Science ®Google Scholar
• Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554–565. doi:10.1053/j.gastro.2013.05.010.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209. doi:10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Lee J, Nebozhyn M, Kim KM, JC T, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–456. doi:10.1038/nm.3850.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Elias AD, Gradishar WJ. NCCN guidelines updates: breast cancer. J Natl Compr Canc Netw. 2018;16:605–610. doi:10.6004/jnccn.2018.0043.
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–271. doi:10.1093/annonc/mdu450.
   PubMed Web of Science ®Google Scholar
• Yan R, Yang X, Wang X, Wang B, Zhao Y, Huang W, Zhao W, Jia L. Association between intra-tumoral immune response and programmed death ligand 1 (PD-L1) in gastric cancer. Med Sci Monit. 2019;25:6916–6921. doi:10.12659/MSM.916432.
   PubMed Web of Science ®Google Scholar
• Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst. 2015;107:dju435.
   PubMedGoogle Scholar
• Melo S, Figueiredo J, Fernandes MS, Goncalves M, Morais-de-Sa E, Sanches JM, Seruca R. Predicting the functional impact of CDH1 Missense mutations in hereditary diffuse gastric cancer. Int J Mol Sci. 2017;18:12.
   Web of Science ®Google Scholar
• Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer. 2010;13:1–10. doi:10.1007/s10120-009-0531-x.
   PubMed Web of Science ®Google Scholar
• Luo W, Fedda F, Lynch P, Tan D. CDH1 gene and hereditary diffuse gastric cancer syndrome: molecular and histological alterations and implications for diagnosis and treatment. Front Pharmacol. 2018;9:1421. doi:10.3389/fphar.2018.01421.
   PubMed Web of Science ®Google Scholar
• Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1:23–32. doi:10.1001/jamaoncol.2014.168.
   PubMed Web of Science ®Google Scholar
• Hakkaart C, Ellison-Loschmann L, Day R, Sporle A, Koea J, Harawira P, Cheng S, Gray M, Whaanga T, Pearce N, et al. Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Maori. Fam Cancer. 2019;18:83–90. doi:10.1007/s10689-018-0080-8.
   PubMed Web of Science ®Google Scholar
• Crunkhorn S. Cancer immunotherapy: targeting regulatory T cells. Nat Rev Drug Discov. 2017;16:754.
   Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109–118. doi:10.1038/cr.2016.151.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949. doi:10.1038/nm1093.
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18:3022–3029. doi:10.1158/1078-0432.CCR-11-3216.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543. doi:10.1073/pnas.0509182102.
   PubMed Web of Science ®Google Scholar
• Xing X, Guo J, Ding G, Li B, Dong B, Feng Q, Zhang J, Ying X, Cheng X, Guo T, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology. 2018;7:e1356144. doi:10.1080/2162402X.2017.1356144.
   PubMed Web of Science ®Google Scholar
• Andrade F, Casciola-Rosen LA, Rosen A. Granzyme B-induced cell death. Acta Haematol. 2004;111:28–41. doi:10.1159/000074484.
   PubMed Web of Science ®Google Scholar
• Jarosch A, Sommer U, Bogner A, Reissfelder C, Weitz J, Krause M, Folprecht G, Baretton GB, Aust DE. Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer. Oncoimmunology. 2018;7(2):e1393133. doi:10.1080/2162402X.2017.1393133.
   PubMed Web of Science ®Google Scholar
• Carotta S, Holmes ML, Pridans C, Nutt SL. Pax5 maintains cellular identity by repressing gene expression throughout B cell differentiation. Cell Cycle. 2006;5:2452–2456. doi:10.4161/cc.5.21.3396.
   PubMed Web of Science ®Google Scholar
• Medvedovic J, Ebert A, Tagoh H, Busslinger M. Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol. 2011;111:179–206.
   PubMed Web of Science ®Google Scholar